Cargando…
Use of Apolipoprotein B in the Era of Precision Medicine: Time for a Paradigm Change?
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death worldwide and the risk of a major cardiovascular event is highest among those with established disease. Ongoing management of these patients relies on the accurate assessment of their response to any prescribed therapy...
Autores principales: | Cole, Justine, Zubirán, Rafael, Wolska, Anna, Jialal, Ishwarlal, Remaley, Alan T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488498/ https://www.ncbi.nlm.nih.gov/pubmed/37685804 http://dx.doi.org/10.3390/jcm12175737 |
Ejemplares similares
-
Accuracy and Clinical Impact of Estimating Low-Density Lipoprotein-Cholesterol at High and Low Levels by Different Equations
por: Sampson, Maureen, et al.
Publicado: (2022) -
Apolipoprotein Mimetic Peptides: Potential New Therapies for Cardiovascular Diseases
por: Wolska, Anna, et al.
Publicado: (2021) -
SAT-656 Both Neutrophil and Monocyte Ratios to High Density Lipoprotein Cholesterol Are Superior Biomarkers of Metabolic Syndrome
por: Ramakrishnan, Neeraj, et al.
Publicado: (2020) -
Dysfunctional Endothelial Progenitor Cells in Metabolic Syndrome
por: Devaraj, Sridevi, et al.
Publicado: (2012) -
Comment on Lopes-Virella et al. Baseline Markers of Inflammation Are Associated With Progression to Macroalbuminuria in Type 1 Diabetic Subjects. Diabetes Care 2013;36:2317–2323
por: Jialal, Ishwarlal, et al.
Publicado: (2014)